You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory DLBCL

Showing 1 - 25 of 9,193
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Apr 10, 2023

DLBCL Trial in Japan (MT-2111)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Nagoya-shi, Aichi, Japan
  • +3 more
Jan 12, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Relapsed or Refractory DLBCL Trial (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Not yet recruiting
  • Relapsed or Refractory DLBCL
  • Anti-PD-1 Antibody Plus Chidamide and Rituximab
  • (no location specified)
Apr 6, 2022

DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)

Recruiting
  • DLBCL
  • Tafasitamab and Lenalidomide
  • Hangzhou, Zhejiang, China
    The First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022

Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 3, 2022

Diffuse Large B Cell Lymphoma Trial (Polatuzumab Vedotin)

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
May 3, 2022

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

Recruiting
  • Diffuse Large B Cell Lymphoma，DLBCL
  • PM 8.4 mg/m2
  • PM 11.2 mg/m2
  • Chengdu, Sichuan, China
    West China Hospital Sichuan University
Jan 15, 2023

Lymphoma, Large B-Cell, Diffuse, Tumors by Histologic Type Trial in China (penpulimab, lenalidomide, Rituximab, Gemcitabine,

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Neoplasms by Histologic Type
  • penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
  • Hefei, Anhui, China
  • +3 more
Mar 3, 2022

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

Including miRNA-based Tumor Signatures in Diffuse Large B Cell

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • no intervention (observational study)
  • Napoli, Italy
  • +2 more
Feb 17, 2023

Diffuse, Large B-Cell, Lymphoma Trial in Italy (GA101_DHAP)

Completed
  • Diffuse, Large B-Cell, Lymphoma
  • Vicenza, VI, Italy
  • +9 more
Mar 3, 2022

DLBCL Trial in Seoul (Tislelizumab, Pemetrexed)

Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 15, 2022

DLBCL (DLBCL) Trial (Tisagenlecleucel)

Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
Feb 25, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Austria (Venetoclax, Obinutuzumab)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Graz, Austria
  • +5 more
Feb 15, 2022

Non-GCB/ABC DLBCL, With and Without MyD88 and/or CD79B Mutations Trial in Cleveland, Toledo (Mivavotinib)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • With and Without MyD88 and/or CD79B Mutations
  • Evanston, Illinois
  • +6 more
Dec 12, 2022

Tafasitamab in Combination With Lenalidomide in Patients withR/R

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Tafasitamab Injection
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 31, 2023

DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

Not yet recruiting
  • DLBCL
  • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
  • Qingdao, Shandong, China
    the affiliated hospital of Qingdao University
Aug 18, 2022

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Münster (L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • L19-IL2 - Ph I
  • +2 more
  • Münster, Germany
    Münster University Hospital
Apr 19, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Borddeaux Cedex, France
  • +9 more
Nov 11, 2022